No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Approval Alert: China’s NMPA Approves Qyuns Therapeutics’ Biosimilar Ustekinumab for Crohn’s Disease
On 12 February 2025, Qyuns Therapeutics Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has accepted the marketing authorisation application and supplemental application for QX001S